Showing 841-850 of 4010 results for "".
Monoclonal Antibody Treatment for COVID-19 Receives FDA Authorization
https://reachmd.com/programs/the-drug-report/monoclonal-antibody-treatment-for-covid-19-receives-fda-authorization/12008/The FDA has granted Emergency Use Authorization, or EUA, for Eli Lilly and Company’s investigational COVID-19 treatment.Measles Vaccination Rates Drop—But Pharmacists Can Help
https://reachmd.com/programs/the-drug-report/measles-vaccination-rates-dropbut-pharmacists-can-help/12037/A staggering number of children have avoided getting the measles vaccination due to the COVID-19 pandemic. How can pharmacists help?FDA Issues EUA for Pfizer-BioNTech COVID-19 Vaccine
https://reachmd.com/programs/the-drug-report/fda-issues-eua-for-pfizer-biontech-covid-19-vaccine/12097/The US Food and Drug Administration issued the first Emergency Use Authorization for a COVID-19 vaccination.CDC Playbook for COVID-19 Vaccine Distribution
https://reachmd.com/programs/the-drug-report/cdc-playbook-for-covid-19-vaccine-distribution/11994/Here's how the Centers for Disease Control and Prevention will leverage pharmacies to help distribute the COVID-19 vaccine.New Pathways in the Treatment of DMD
https://reachmd.com/programs/cme/new-pathways-in-the-treatment-of-dmd/48924/The Duchenne muscular dystrophy (DMD) treatment landscape continues to evolve, with promising therapies emerging from new insights into disease biology. This activity explores the role of aberrant histone deacetylase (HDAC) activity in DMD pathophysiology, including its impact on inflammation, muscl"Psleep": Psoriasis and Sleep
https://reachmd.com/programs/practical-dermatology-focus-psoriasis/psleep-psoriasis-and-sleep/29075/The “invisible” impacts of psoriasis are those not directly seen on examination. These include itch, pain, fatigue and sleep dysfunction, which may be improved by our systemic therapies. However, there is a gap between the patients’ reporting of these experienced invisible impacts and their physiciaThe LDL-C Gap in Statin-Treated Patients: A Population-Level Problem with Economic Consequences
https://reachmd.com/programs/heart-matters/the-ldl-c-gap-in-statin-treated-patients-a-population-level-problem-with-economic-consequences/37199/Patients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL
https://reachmd.com/programs/cme/asparaginase-based-treatment-young-adults-all/37193/Are you up to date on treatment strategies for young adults with acute lymphoblastic leukemia (ALL)? Evolving evidence and clinical guidelines now strongly support the use of asparaginase-based, pediatric-inspired regimens over traditional adult protocols for young adults with ALL. However, many patPrecision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies
https://reachmd.com/programs/cme/precision-strikes-in-aml-navigating-the-evolving-landscape-of-targeted-therapies/48856/Explore AML treatments targeting FLT3 and KMT2A/NPM1, focusing in on molecular diagnostics, clinical data, therapy sequencing, and adverse event management.Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
https://reachmd.com/programs/cme/chairpersons-perspective-novel-treatments-for-newly-diagnosed-ph-cml-cp-striking-the-balance-of-treatment-with-patient-goals-and-qol/28646/Join Dr. Jorge Cortes and learn about best practices for selecting optimal treatment plans for newly diagnosed Ph+ CML-CP.